本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Can-Fite Biopharma Ltd

4.40
+0.06001.38%
成交量:8,496.00
成交額:3.70萬
市值:576.05萬
市盈率:0.00
高:4.44
開:4.40
低:4.23
收:4.34
52周最高:46.60
52周最低:3.36
股本:130.92萬
流通股本:123.88萬
量比:0.06
換手率:0.69%
股息:- -
股息率:- -
每股收益(TTM):-2,665.2840
每股收益(LYR):-3,259.3317
淨資產收益率:-264.12%
總資產收益率:-81.86%
市淨率:1.38
市盈率(LYR):0.00

資料載入中...

2025/07/25

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2025/07/25

SEC問詢函

Form CORRESP - Correspondence
2025/07/25

SEC問詢函

Form CORRESP - Correspondence
2025/07/23

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2025/07/17

SEC問詢函

Form CORRESP - Correspondence
2025/04/14

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/11/14

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/06

SEC問詢函

Form CORRESP - Correspondence
2024/04/05

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/28

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/14

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/01/03

SEC問詢函

Form CORRESP - Correspondence
2023/09/11

SEC問詢函

Form CORRESP - Correspondence
2023/04/21

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/30

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/10

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2023/02/08

SEC問詢函

CORRESP [Cover] - Correspondence
2023/01/31

招股説明書

F-1 - Registration statement for certain foreign private issuers
2022/03/24

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals